MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Compelling Results for DA-1241 in Phase 2a MASH Trial On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) announced positive topline results from ...

Ildong Pharmaceutical stated on the 19th that it will supplement the clinical trial data for the oral antiviral drug ...

(RTTNews) - MetaVia Inc. (MTVA), Wednesday announced positive 16-week results from the two-part Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated ...

Report by Parlance: 87% of healthcare leaders interested in AI have yet to implement it. The majority express a strong desire ...

Blueprint Medicines Corporation today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2025 outlook at the 43rd Annual J.P. Morgan Healthcare Conference on ...

"Achieving the primary endpoint of a reduction in ALT levels through direct hepatic effects, as well as notable secondary endpoints, including significantly lower HbA1C levels compared to the placebo, ...

We are republishing the latest research report under the MTVA ticker. Topline Results from Phase 2a Trial of DA-1241 in MASH Expected in December 2024 MetaVia Inc. is developing DA-1241 as a ...

MetaVia Inc. is developing DA-1241 as a treatment for metabolic dysfunction-associated steatohepatitis (MASH; formerly NASH). DA-1241 is a novel chemical entity that selectively activates GPR119 ...

The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel ...